AGC (Headquarters: Tokyo; President: Takuya Shimamura) has announced that AGC has decided to increase the production capacity of its biopharmaceutical CDMO^*1 subsidiary, AGC Biologics (Headquarters: United States). AGC Biologics will construct a new building on land adjacent to its current Copenhagen site, adding production floors with 2,000L single-use bioreactors^*2, labs and office space. The total investment for this expansion is estimated to be around 20 billion JPY, and the start of operation is scheduled for 2023.

Under AGC plus management policy, AGC Group has positioned its Life Science business including its biopharmaceutical CDMO services, as one of its strategic businesses. The Group has been expanding its Life Science business through multiple acquisitions and capital investments in biopharmaceutical services using mammalian cells and microorganisms, as well as in synthetic pharmaceutical and agrochemical services. Most recently, in July 2020, AGC expanded the scope of CDMO services into the rapidly growing gene and cell therapy fields through the acquisition of Molmed S,p.A (now AGC Biologics S.p.A.). AGC’s Life Science business is expecting to achieve its initial 2025 sales target of 100 billion yen, two to three years ahead of its original plan.
AGC continues to strive to be a company that actively contributes to the pharmaceutical companies, patients, and the wider society as a whole.